



## HOOKIPA Pharma to Present at Upcoming Conferences in May

April 29, 2020

NEW YORK and VIENNA, Austria, April 29, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, 'HOOKIPA'), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that HOOKIPA's management team will participate in the following virtual investor conferences in May:

- SunTrust Robinson Humphrey 6th Annual Life Sciences Summit, May 5 - 6, 2020
- Bank of America Global Research Health Care Conference 2020, May 12 - 14, 2020
- RBC Capital Markets Global Healthcare Conference, May 19 - 20, 2020, including a [webcast presentation at 8:00 a.m. ET on May 19](#)

The live audio webcast of the presentation held at the RBC Capital Markets Global Healthcare Conference will be available within the Investors & Media section of HOOKIPA's website at <https://ir.hookipapharma.com/events>. An archived replay will be accessible for 30 days following the event.

### About HOOKIPA

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system.

HOOKIPA's proprietary arenavirus-based technologies, VaxWave<sup>®</sup>, a replication-deficient viral vector, and TheraT<sup>®</sup>, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8<sup>+</sup> T cells and pathogen-neutralizing antibodies. Both technologies are designed to allow for repeat administration to augment and refresh immune responses. TheraT<sup>®</sup> has the potential to induce CD8<sup>+</sup> T cell response levels previously not achieved by other immuno-therapy approaches. HOOKIPA's "off-the-shelf" viral vectors target dendritic cells in vivo to activate the immune system.

HOOKIPA's VaxWave<sup>®</sup>-based prophylactic Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial in CMV-negative patients awaiting kidney transplantation from living CMV-positive donors as well as CMV-positive patients awaiting kidney transplantation from CMV-positive or -negative donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and chronic Hepatitis B infections.

In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The TheraT<sup>®</sup> based lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus16-positive cancers. The Phase 1/2 clinical trial for HB-201 was initiated in December 2019. The HB-202 IND submission is intended for the first half of 2020.

Find out more about HOOKIPA online at [www.hookipapharma.com](http://www.hookipapharma.com).

### HOOKIPA Forward Looking Statements

Certain statements set forth in this press release constitute "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as "believes," "expects," "plans," "potential," "would" or similar expressions and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA's research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA's ability to successfully establish, protect and defend its intellectual property, risks relating to business interruptions resulting from the coronavirus (COVID-19) disease outbreak or similar public health crises and other matters that could affect the sufficiency of existing cash to fund operations and HOOKIPA's ability to achieve the milestones under the agreement with Gilead. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see HOOKIPA's annual report on Form 10-K for the full year ended December 31, 2019 which is on the Security and Exchange Commission's website at [www.sec.gov](http://www.sec.gov) and HOOKIPA's website at [www.hookipapharma.com](http://www.hookipapharma.com).

Investors and others should note that we announce material financial information to our investors using our investor relations website (<https://ir.hookipapharma.com/>), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website.

For further information, please contact:

**Media**  
Nina Waibel

**Investors**  
Matt Beck

Senior Director - Communications  
[nina.waibel@hookipapharma.com](mailto:nina.waibel@hookipapharma.com)

Executive Director - Investor Relations  
[matthew.beck@hookipapharma.com](mailto:matthew.beck@hookipapharma.com)

**Media enquiries**

Instinctif Partners

[hookipa@instinctif.com](mailto:hookipa@instinctif.com)

+44 (0)20 7457 2020